Ilias Läber

Panalpina Welttransport (Holding) AG engages in the provision of freight transportation and logistics services. It offers air freight, ocean freight, energy solutions, supply chain solutions, road and rail services, security, business implementation, and online tools. It operates through the following geographical segments: Asia Pacific; Europe; Middle East, Africa, and CIS; and Americas. The company was founded in 1954 and is headquartered in Basel, Switzerland.

Swiss Automotive Group AG engages in the manufacture and distribution of car and commercial vehicle spare parts. The firm also sells repair parts, lubricants, chemicals, accessories, workshop equipment, and consumables. It also provides maintenance and repair services. The company was founded in 2009 and is headquartered in Cham, Switzerland.

Cevian Capital AG (Cevian) is an independent alternative investment management firm headquartered in Pfäffikon, Switzerland. The firm was founded by Lars Förberg and Christer Gardell in 2007. Cevian manages assets of pension funds, endowments, foundations and sovereign wealth funds.

Spectrum Value Management Ltd. is a singe-family office headquartered in Rapperswil-Jona, Switzerland. The firm was founded in 2002 and it manages and looks after the commercial and private interests of Thomas Schmidheiny Family, a Swiss industrialist family with a long and rich entrepreneurial heritage.

Mckinsey & Co. (Switzerland) provides business management consulting services. The private company is based in Geneva, Switzerland.

Quercis Pharma AG is a private biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is focused on developing a pipeline of late-stage clinical studies that aim to prevent venous thromboembolism (VTE) in cancer patients. The Swiss company's lead drug candidate acts as an antithrombotic with significantly lower risk of adverse events than existing treatments. Quercis Pharma also targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola, and COVID-19. The company is preparing to conduct a number of studies for the treatment of SCD (phase 2) and COVID-19 (phase 2/3). Quercis plans to initiate two phase 3 studies for the prevention of VTE in pancreatic cancer and glioblastoma patients and will pursue FDA approval for the prevention of VTE in all cancer types based on these studies. The company was founded in 2019 by Thomas Lines, who has been the CEO since then.